Persistent Asset Partners Ltd Makes New $1.59 Million Investment in United Therapeutics Corporation $UTHR

Persistent Asset Partners Ltd purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 3,267 shares of the biotechnology company’s stock, valued at approximately $1,592,000.

A number of other hedge funds have also recently added to or reduced their stakes in UTHR. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC acquired a new stake in United Therapeutics in the 2nd quarter worth about $277,000. Cerity Partners LLC raised its holdings in shares of United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia raised its holdings in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Price Performance

United Therapeutics stock opened at $548.27 on Wednesday. The company has a market cap of $23.27 billion, a price-to-earnings ratio of 20.24, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock’s 50-day moving average is $566.12 and its 200-day moving average is $522.52.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 earnings per share. Research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $549.15, for a total transaction of $5,216,925.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,247,713.95. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $549.17, for a total value of $5,491,700.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,366,132.92. The trade was a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 644,468 shares of company stock worth $363,647,822. 8.60% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.